Recombinant Proteins

Recombinant Proteins(重组蛋白)

Recombinant proteins are a new combination of genes that forms DNA. Recombinant DNA technology allows for the production of wild type and modified human and mammalian proteins at bulk quantities. Recombinant proteins are made from cloned DNA sequences which usually encode an enzyme or protein with known function

Recombinant proteins are made through genetic engineering, also called gene splicing or recombinant DNA technology. By putting human, animal or plant genes into the genetic material of bacteria, mammalian or yeast cells, these microorganisms can be used as factories or producers to make proteins for medical, academic and research uses.

A vector is simply a tool for manipulating DNA and can be viewed as a "transport vehicle" for the production of proteins from specific DNA sequences cloned into them. Purification and expression of a protein can sometimes be quite complicated & time-consuming, therefore an additional tag is used in addition to the specific DNA sequence which will facilitate the purification & expresion of the recombinant protein.

Recombinant Proteins are proteins that their DNA that has been created artificially. DNA from 2 or more sources which is incorporated into a single recombinant molecule. The DNA is first treated with restriction endonuclease enzyme which the ends of the cut have an overhanging piece of single-stranded DNA. These are called "sticky ends" because they are able to base pair with any DNA molecule containing the complementary sticky end. DNA ligase covalently links the two strands into 1 recombinant DNA molecule.

Recombinant DNA molecule must be replicated many times to provide material for analysis & sequencing. Producing many identical copies of the same recombinant DNA molecule is called cloning. Cloning is done in vitro, by a process called the polymerase chain reaction (PCR). Cloning in vivo can be done in unicellular microbessuch as E. coli, unicellular eukaryotes like yeast and in mammalian cells grown in tissue culture.

Recombinant DNA must be taken up by the cell in a form in which it can be replicated and expressed. This is achieved by incorporating the DNA in a vector. A number of viruses (both bacterial and of mammalian cells) can serve as vectors.

Recombinant DNA is also sometimes referred to as chimera. When combining two or more different strands of DNA.There are 3 different methods by which Recombinant DNA is made. 1. Transformation, 2. Phage-Transfection 3.Yeast, Plant & Mammalian Transformation. When using the method of transformation one needs to select a piece of DNA to be inserted into a vector, cut a piece of DNA with a restriction enzyme and ligate the DNA insert into the vector with DNA Ligase. The insert contains a selectable marker which allows for identification of recombinant molecules. An antibiotic marker is used in order to cause death for a host cell which does not contain the vector when exposed to a certain antibiotic.

Trasnformation is the insertion of the vector into the host cell. The host cells are prepared to take up the foreign DNA. Selectable markers are used for antibiotic resistance, color changes, or any other characteristic which can distinguish transformed hosts from untransformed hosts. Yeast, Plant & Mammalian Transformation is done by micro-injecting the DNA into the nucleus of the cell being transformed. Phage-Transfection process, is equivalent to transformation except for the fact that phage lambda or MI3 is used instead of bacteria.

These phages produce plaques which contain recombinant proteins which can be easily distinguished from the non-recombinant proteins by various selection methods.

Significant amounts of recombinant protein are produced by the host only when expression genes are added. The Protein’s expression depends on the genes which surround the DNA of interest, this collection of genes act as signals which provide instructions for the transcription and translation of the DNA of interest by the cell. These signals include the promoter, ribosome binding site, and terminator.

The recombinant DNA is inserted into expression vectors which contain the promoter, ribosome binding site, and terminator.

In prokaryotic systems, the promoter, ribosome binding site, and terminator have to be from the same host since the bacteria is unlikely to understand the signals of human promoters and terminators. The designated gene must not contain human introns since the bacteria does not recognize it and this results in premature termination, and the recombinant protein may not be processed correctly, be folded correctly, or may even be degraded.

The peptide sequence can be added as an extension at the N-terminal. Researchers can select the specific purification system which they would like to use. The unique vectors available contain several features needed for the production of bulk quantities of the target protein. The peptide sequence is usually placed in the vector so that it is designed to be a point of attack for a specific protease. Thus, after the recombinant protein is expressed and extracted from bacteria, specific peptide extension can be used to purify the protein and subsequently removed from the target protein to generate a nearly natural sequence on the final product.

6 or more consistent Histidine residues act as a metal binding site for recombinant protein purification and expression. The hexa-His sequence is called a His-Tag sequence which can be placed on the N-terminal of a target protein by using vectors from various commercial molecular biology companies. The His-Tag contains a cleavage site for a specific protease. His-Tag recombinant proteins are purified by Metal Chelate Affinity Chromatography such as nickel ion columns that are used as the heavy metal ion and the His-Tag protein is eluted from the metal-chelate column with Histidine or imidazole. Then the purified His-Tag protein is treated with the specific protease to cleave off the His-Tag or not if the tag doesn’t affect the active site of the protein.

Proteins have metal binding sites which can be used for the purification of recombinant and natural proteins. This type of purification is rather simple when using a gel bead which is covalently modified so that it displays a chelator group for binding a heavy metal ion like Ni2+ or Zn2+. The chelating group on the gel bead contains a small amount of the ligands needed to hold the metal ion. So when the protein’s metal binding site finds the heavy metal, it will bind by providing the ligands from its metal binding site to attach to the metal ion displayed on the chelator location of the gel bead. This purification method is quite identical to affinity chromatography when purifying metal-binding class of proteins.

研究方向

Recombinant Proteins 相关产品(2687)

  • GC63958 structure
    GC639586α-Hydroxy Paclitaxel-d5
    CAS: 1315376-90-9

    6α-Hydroxy Paclitaxel-d5 是 6α-Hydroxy paclitaxel 的氘代物。6α-Hydroxy paclitaxel 是紫杉醇的初级代谢物。6α-Hydroxy paclitaxel 对有机阴离子转运多肽 1B1/SLCO1B1 (OATP1B1) 具有与紫杉醇相似的时间依赖性抑制效力,但它对 OATP1B3 不具有时间依赖性作用。6α-Hydroxy paclitaxel 可用于癌症研究。

  • GC63975 structure
    GC63975Acanthoside B
    CAS: 7374-79-0

    Acanthoside B 是一种具有抗炎、抗遗忘活性的生物活性木脂素。Acanthoside B 可用于阿尔茨海默病和肺部炎症等疾病的研究。

  • GC64119 structure
    GC64119Saponarin
    CAS: 20310-89-8

    A flavonoid glycoside with diverse biological activities

  • GC64212 structure
    GC64212Valategrast hydrochloride
    CAS: 828271-96-1

    Valategrast hydrochloride (R-411) 是一种有效的整联蛋白 α4β1 (VLA-4) 和 α4β7 双重拮抗剂。Valategrast hydrochloride 可用于慢性阻塞性肺疾病 (COPD) 和哮喘的研究。

  • GC64255 structure
    GC64255CHIC35
    CAS: 848193-72-6

    CHIC35 是 EX-527 的结构类似物,是 SIRT1 (IC50=0.124 µM) 的有效选择性抑制剂。CHIC35 对 SIRT1 的选择性远大于对 SIRT2 (IC50=2.8 µM) 和 SIRT3 (IC50>100 µM)。CHIC35 具有抗炎作用,可用于 CHARGE 综合征的研究。

  • GC64527 structure
    GC64527ADTL-SA1215
    CAS: 782387-91-1
    纯度: >99.00%

    ADTL-SA1215 是一种调节三阴性乳腺癌自噬的特异性 SIRT3 小分子激活剂。

  • GC64571 structure
    GC64571Sibrafiban
    CAS: 172927-65-0

    Sibrafiban (RO 48-3657) 是一种 Ro 44-3888 的具有口服活性的,非肽,双重前药,是一种选择性的糖蛋白 IIb/IIIa 受体 (glycoprotein IIb/IIIa receptor) 拮抗剂。Sibrafiban 可抑制血小板聚集。

  • GC64575 structure
    GC64575Et-29
    CAS: 2166487-23-4
    纯度: >99.00%

    Et-29 是一种有效的,选择性的 SIRT5 抑制剂 (Ki=40 nM)。

  • GC64932 structure
    GC64932αvβ5 integrin-IN-1
    CAS: 2615912-33-7
    纯度: >99.00%

    αvβ5 integrin-IN-1 是第一个有效和选择性 αvβ5 整合素抑制剂(pIC50 = 8.2)。

  • GC64946 structure
    GC64946SRT 2183
    CAS: 1001908-89-9
    纯度: >98.00%

    SRT2183 is a small-molecule activator of the sirtuin subtype SIRT1, currently being developed by Sirtris Pharmaceuticals.

  • GC65019 structure
    GC65019SRT 1460
    CAS: 925432-73-1
    纯度: >98.00%

    SRT-1460 is a potent and selective activator of Sirtuin 1 (SIRT1) with EC1.5 of 2.9 μM. SRT-1460 reduces cell viability and growth of pancreatic cancer cells and induces apoptosis.

  • GC65030 structure
    GC65030Sirtuin modulator 2
    CAS: 667910-69-2

    Sirtuin modulator 2 (Compound 132) 是一种 sirtuin 调节剂,ED50 不超过 50 μM。

  • GC65322 structure
    GC65322FABPs ligand 6
    CAS: 2988135-14-2
    纯度: >98.00%

    FABPs ligand 6是一种FABP5和FABP7抑制剂,对FABP5和FABP7的K d 值分别为874nM和20nM。

  • GC65383 structure
    GC65383RAD51-IN-2
    CAS: 2301085-04-9
    纯度: >99.00%

    RAD51-IN-2 (化合物 example 67A) 是一种 RAD51 抑制剂,详细信息请参考专利文献 WO2019/051465A1。

  • GC65455 structure
    GC65455c(phg-isoDGR-(NMe)k)
    CAS: 1844830-65-4

    c(phg-isoDGR-(NMe)k) 是有效选择性的 α5β1 整合素 配体,IC50 为 2.9 nM。

  • GC65581 structure
    GC65581MIND4-19
    CAS: 129544-85-0

    MIND4-19 是一种有效的 SIRT2 抑制剂,IC50 为 7.0 μM。MIND4-19 可用于亨廷顿氏舞蹈症 (Huntington's disease) 的研究。

  • GC65597 structure
    GC65597Abciximab
    CAS: 143653-53-6
    纯度: >99.00% / >95.50%

    Abciximab (C7E3) 是一种小鼠/人嵌合单克隆抗体,是一种糖蛋白 IIb/IIIa(glycoprotein IIb/IIIa)抑制剂。 Abciximab 通过与糖蛋白 IIb/IIIa、vitronectin 和 Mac-1 受体结合抑制血小板聚集和白细胞粘附。

  • GC65909 structure
    GC65909Bexotegrast
    CAS: 2376257-44-0
    纯度: >98.00%

    Bexotegrast 是 αΝβ6 整合素的有效抑制剂。Bexotegrast 可用于研究特发性肺纤维化 (IPF) 和非特异性间质性肺炎 (NSIP) 等纤维化 (信息摘自专利 WO2020210404A1,compound 5)。

  • GC65935 structure
    GC65935CAM833
    CAS: 2758364-02-0
    纯度: >99.50% / >98.00%

    CAM833是一种亚微摩尔化学抑制剂,可抑制肿瘤抑制因子BRCA2的RAD51重组酶和BRC重复基序之间的调节蛋白相互作用。

  • GC66026 structure
    GC66026SIRT2-IN-9
    CAS: 522650-91-5
    纯度: >99.00%

    SIRT2-IN-9 (compound 12) 是 SRIT2 的选择性抑制剂,IC50 值为 1.3 μM。SIRT2-IN-9 抑制 MCF-7 乳腺癌细胞的增殖活性。SIRT2-IN-9 可用于癌症的研究。

  • GC67708 structure
    GC67708PLN-1474
    CAS: 2408065-32-5
    纯度: >99.00%

    PLN-1474 (compound 1) 是具有口服活性的,选择性的 av&szlig;1 整合素抑制剂,IC50 值 <50 nM。PLN-1474 在肝纤维化小鼠模型中显著降低肝脏 pSMAD3/SMAD3 水平、肝脏胶原蛋白基因表达和肝脏 OHP 浓度。PLN-1474 可用于预防、延缓或治疗纤维化或肝硬化疾病或紊乱的研究。

  • GC67778 structure
    GC67778Sirtuin modulator 3
    CAS: 708995-11-3

    Sirtuin modulator 3 (compound 129) 是一种 N -苯基苯甲酰胺衍生物,作为 Sirtuin 调制剂。

  • GC67888 structure
    GC67888RAD51-IN-5
    CAS: 2690367-19-0

    RAD51-IN-5 是一种有效的 RAD51 抑制剂。RAD51 是一种真核生物基因。RAD51-IN-5 具有研究线粒体缺陷病症的潜力 (摘自专利 WO2021164746A1,化合物 3)。

  • GC68283 structure
    GC68283Etrolizumab
    CAS: 1044758-60-2

    Etrolizumab (rhuMAb Beta7) 是一种肠道选择性抗-β7 整合素单克隆抗体。Etrolizuma b是针对 α4β7 和 αEβ7 整合素的 β7 亚基的特异性靶向药物。Etrolizumab 可用于炎症性肠病 (IBD) 的研究。